Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

PharmNovo starts clinical phase I studies of a drug candidate for neuropathic pain

PharmNovo AB, a Swedish pharmaceutical company developing drugs for neuropathic pain, so-called nerve pain, today announces that phase I studies of the drug candidate PN6047 have been initiated.The drug candidate PN6047 from PharmNovo is an entirely new drug. The substance is a selective delta opioid, a so-called DORA (delta opioid receptor agonist), which, in animal models, effectively relieves nerve pain. It does so without causing the unwanted side effects of conventional opioid drugs on the market today. During the summer, the application to start clinical studies of PN6047 was

Scandion Oncology receives approvals for next parts of the CORIST trial

The development of SCO-101 will continue as planned with expansion of the CORIST trial expected to commence during the third quarter of 2022.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has now received approvals from authorities and ethical committees in Denmark and Germany for the next parts of the ongoing CORIST phase II-trial. The trial studies Scandion’s lead compound SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC). Thus, the

Interim Report 220101-220630

Press Release 19 August, 2022Summery of Interim Report First to Second Quarter 2022(2022-01-01 – 2022-06-30) • Operating income amounted to 903 789 (528 702) SEK. • Earnings after financial items amounted to - 5 911 082 (-4 008 690) SEK. • Earnings per share * amounted to SEK -0.18 (-0.18). • Equity / assets ratio was 93% (83%). Second Quarter 2022(2022-04-01 – 2022-06-30) • Operating income amounted to 685 380 (527 625) SEK. • Earnings after financial items amounted to - 3 209 011 (-2 229 708) SEK. • Earnings per share * amounted to SEK – 0.10 (-0.10). *

Sanolium AB interim report, April – June 2022

Revenue in the second quarter amounted to 219.5 (195.8) MSEK, representing an increase of 12.1%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional Services revenue are attributable to the development of the existing product as well as the Sussa project. Adjusted EBITDA in the second quarter amounted to 61.0 (46.1) MSEK resulting in an adjusted EBITDA margin of 27.8 (23.5) %. Employee related expenses amounted to 123.1 (117.8) MSEK, representing an increase of 4.5 %. The number of full time equivalents (FTE) was 702 at the end of

Jan Gurander to step down as Volvo Group Deputy CEO

Jan Gurander will step down as Volvo Group Deputy CEO as of December 31[st], 2022. His other managerial assignments within the Group will gradually be distributed to other members of the Volvo Group Executive Board. After the turn of the year, Jan Gurander will stand available to President and CEO Martin Lundstedt´s disposal.Jan Gurander has a long and successful career within the Volvo Group, starting as Volvo Group Chief Financial Officer in 2014. He held the role of acting President and CEO for parts of 2015 and was appointed Deputy CEO in 2016. Prior to his career in the Volvo Group,

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2022

The clinical development of fostrox remains our focus  April – June Financial summary for the quarter · Net turnover amounted to SEK 0.5 (0.9) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -21.5 (-17.1) million. Basic and diluted earnings per share amounted to SEK -0.42 (-0.31) and SEK -0.42 (-0.31) respectively. · Cash flow from operating activities amounted to SEK -17.6 (-21.9) million. · Cash and cash equivalents at the end of the period amounted to SEK 162.8 (247.8) million.   Significant events during the

HODL SPAC Europe AB: Half-year report 2022

HODL SPAC Europe AB (publ) hereby publishes the interim report for the period January – June 2022.  The interim report is available as an attached document and on the company's website (www.hodlspac.se). Below is a summary of the report.Half-year 2022[1] ●        Earnings per share amounted to SEK -0.05 (--). ●        Profit after tax amounted to TSEK -428,5  (--). ●        Cash and cash equivalents at 30 June 2022 amounted to TSEK 29 173,8  (--). Second quarter 2022 ●        Earnings per share amounted to SEK -0.02 (--). ●        Profit after tax amounted to TSEK -428,5  (

Heliospectra (publ) Publish the Half-Year Report for January-June 2022

(GOTHENBURG, Sweden, Aug 19, 2022, at 08:30 CET)– Heliospectra AB (publ), a leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its Half-Year Report for January-June 2022.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/reports-documents-archive. SUMMARY OF REPORT SALES AND FINANCIAL PERFORMANCE APRIL-JUNE · Order intake during the period April - June amounted to SEK 5,346 (-61,492) thousand. · Net sales during the period April - June amounted to SEK 3,

Second quarter report Q2-2022 – green light for the pivotal trial 0205

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2022. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. The Company is progressing with planned activities: Recruitment of trial 0206 was completed (a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures) and finally regulatory approval was received and thereby a green light to initiate recruitment of the pivotal trial 0205 with CT001, a

BioStock: Cyxone comments on scientific T20K article

This week, the scientific journal Biomedicine & Pharmacotherapy published an article regarding T20K, Cyxone's drug candidate in multiple sclerosis. Behind the article are Christian Gruber and researchers at the Medical University of Vienna. The authors report findings indicating that T20K may have an effect on anaplastic large cell lymphoma. BioStock contacted Cyxone's acting CEO Carl-Magnus Högerkorp to find out more.Read the interview with Cyxone's acting CEO Carl-Magnus Högerkorp at biostock.se: https://www.biostock.se/en/2022/08/cyxone-comments-on-scientific-t20k-article/ This is

Glaston Oyj Abp - Managers' Transactions

Glaston Corporation     Stock Exchange Release, Managers' Transactions 19.8.2022 at 9.15 amGlaston Oyj Abp - Managers' Transactions____________________________________________Person subject to the notification requirementName: Veli-Matti ReinikkalaPosition: Member of the Board/Deputy member Issuer: Glaston Oyj AbpLEI: 743700V3I7CLI3DJ8L62Notification type: INITIAL NOTIFICATIONReference number: 18589/9/8____________________________________________ Transaction date: 2022-08-17Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000369657Nature of the

CONTINUED GROWTH AND PROFITABILITY

This is a translation of the Swedish interim report. If there should be any discrepancies, the Swedish language version governs.  SECOND QUARTER, APRIL – JUNE 2022 · Net sales increased by 10.2%, or 7.9% FX adjusted, to MSEK 86.5 (78.5) · Gross profit increased by 9.3%, or 6.5% FX adjusted, to MSEK 67.0 (61.3) · EBIT was MSEK 9.6 (11.7) · Earnings after tax was MSEK 9.0 (10.7) · Earnings per share was SEK 1.14 (1.35)  FIRST HALF YEAR, JANUARY – JUNE 2022 · Net sales increased by 10.9%, or 8.8% FX adjusted, to MSEK 166.4 (150.1) · Gross profit increased by

INTERIM REPORT Image Systems AB (publ) January-June 2022

Sustainable improvement of margins The Group's strategy to establish a centre of excellence in non-contact measuring technology calls for a conversion of activities as well as a heavy emphasis on product development. Under these conditions, the Group continues to deliver margin improvements, in terms of both the gross margin and the EBITDA margin, which strengthens our conviction that the chosen strategy is the right way forward to achieve profitable growth in the long term.Second quarter April–June Interim period January–June · Order intake amounted to MSEK · Order

Heimstaden Q2 2022 Results

Highlights · Rental income SEK 3.3 billion (3.2). · Investment properties SEK 342 billion and 154,965 homes. · Real economic occupancy 98.5% (98.5%). · Net LTV 50.5% (48.5%) and ICR 2.8x (3.0x). · Heimstaden Bostad Bought 1,091 homes in Germany and 2,009 homes in Finland. · Joint Venture established with the Danish developer Stadt A/S for a 3,000-unit residential project in the Århus area. · Issued SEK 500 million bond and reduced the bridge facility to SEK 3,500 million. · Sold country management organisation to Heimstaden Bostad in July. · Prolonged the

Heimstaden Bostad Q2 2022 Results

Highlights · Rental income SEK 3.1 billion (3.0). · Investment properties SEK 336 billion and 153,287 homes. · Real economic occupancy 98.5% (98.5%). · Net LTV 46.5% (44.5%) and ICR 4.0x (3.9x). · Bought 1,091 homes in Germany and 2,009 homes in Finland. · Bought back hybrid bonds at EUR 868 million in July, funded with equity from shareholders. · Bought the country management organisation from Heimstaden AB in July.CEO Patrik Hall comments: “Despite volatility in capital markets, we deliver strong financial and operational results. Record high occupancy combined

Invitation to conference call with web presentation of AcadeMedia's full year result for July - June 2021/22

AcadeMedia's full year result for July - June 2021/22 will be published at 08:00 CEST on Tuesday 30 August. A web-cast telephone conference will be held at 09:30 CEST the same day, where CEO Marcus Strömberg and CFO Katarina Wilson will present the report.   The presentation will be held in English and can be followed on the web or over the phone. It will be followed by a Q&A session.   To participate in the conference call, and thereby be able to ask questions, call one of the following numbers ten minutes before the start of the call: SE: +46 8 505 583 75 UK: +44 33 3300

UNION therapeutics announces presentation of new data on orismilast at the 31[st] EADV Congress

· Oral presentation of new preclinical data on pharmacological properties of orismilast at the EADV Congress · Additional e-poster details the safety and efficacy of orismilast IR (immediate release) tablets in adults with moderate to severe psoriasis and the development of orismilast MR (modified release) tablets · Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development for the treatment of psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS)   Hellerup, Denmark, 19 August 2022 – UNION therapeutics A/S (UNION),

Håkan Sörman proposed as new Chairman and Mikael Helmerson as a new member of the Board of Directors of AcadeMedia

The Nomination Committee of AcadeMedia will propose that Håkan Sörman, member of AcadeMedia’s Board since 2017, shall be elected as new Chairman and Mikael Helmerson as a new member of the Board at AcadeMedia’s Annual General Meeting on 30 November 2022. Anders Bülow has announced that he declines re-election. The Nomination Committee’s complete proposal to the AGM 2022 will be presented in the notice to attend the AGM. Mikael Helmerson has long experience, including from his time as CEO of Roxtec AB, of leading and developing growth companies characterized by global operations, complex

Peab builds swimming pool facility in Malung

Peab has been commissioned to build a new swimming pool facility in Malung. The customer is Malung-Sälen Municipality and the contract is worth SEK 216 million.Peab will build the new 5,400 m2 swimming pool facility in central Malung. It will contain a 25 meter pool with eight swimming lanes, a multi-pool with a height adjustable bottom, a children’s section as well as a relaxation area with a hot pool, ice swimming hole and a sauna for rent. The entrance to the swimming pool facility will have a cafeteria that also serves people in the swimming area. “We’re very proud to have received

Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn

Gothenburg, August 19, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces that it will present updates on the company’s progress and scientific results at meetings to be held in August, September and October 2022.Elin Rosendahl, VP Clinical Development, will present a poster entitled “Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19” at the

Interim report January-June 2022

Second quarter: April - June 2022 · Revenues from the gaming operation amounted to mSEK 4.2 (8.0), corresponding to a decrease of 47 percent · B2B revenues amounted to mSEK 1.8 (2.6), a decrease of 30 percent · B2C revenues amounted to mSEK 2.4 (7.1), a decrease of 66 percent · Total revenues amounted to mSEK 4.3 (13.9) · EBITDA decreased to mSEK -23.3 (-13.3) · Net result decreased to mSEK -27.3 (-16.9) · Earnings per share amounted to SEK -1.2 (-0.8) · The Board made a proposal to the coming extra general meeting of a fully guaranteed rights issue of mSEK 101 ·

Continued strong growth for Bio-Works

Bio-Works’ net sales increased for the sixth period in a row, growing 119% in the first six months of 2022. The first half in reviewJan – Jun 2022(Jan – Jun 2021) · Net sales increased by 119% to 18.1 MSEK (8.3) with sales growth in all regions. The North American market grew fastest in the first half of the year, accounting for over 6 MSEK in total sales. · Order intake increased by 90% to 22.2 MSEK (11.8). · Operating loss increased by 6% to -23.5 MSEK (-22.1 excluding one-time revenues received as part of the Amicogen technology transfer agreement). · Earnings per

There are no items matching the current filter
There are no more items matching the current filter
Back to top